Slingshot Therapeutics

Slingshot, the Syncona Accelerator, is focused on accumulating a pipeline of early-stage programmes, identified from world-leading academic institutions, and accelerating their development towards the clinic.

Slingshot benefits from Syncona’s expertise in creating and building companies from early-stage science. Through a high-quality management team, Slingshot offers academic founders access to development expertise that is rarely available to singular early-stage programmes, as well as centralised resource, funding and operational support. This enables Slingshot to rapidly advance its programmes and create a variety of options to further progress them through the clinic and ultimately to patients.

Slingshot is led by Managing Partner Edward Hodgkin, as Executive Chair of the company, and Executive Partner Richard Wooster, as Chief Scientific Officer of the company.

Syncona added Slingshot to the portfolio with an initial commitment of £12.5 million. These proceeds will be used to support Slingshot’s operational build and platform development, as well as advance its first programme, Apini, a small molecule programme targeting inflammatory disease that was sourced from The University of Manchester.